Sign in
TerminatedPhase 1/2

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Key facts

Who runs it
Shenzhen Geno-Immune Medical Institute
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
100 people enrolled
Started
1 Jun 2026
Ended
31 Jul 2026
Type of study
Interventional
Treatments tested
  • pathogen-specific CTLs
Record updated
2 November 2026

Who can take part

Age
6 months to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Subjects with or without hematopoietic stem cell transplantation / organ transplant recipients need to meet the following conditions:
  • Evidence of CMV, EBV, ADV, BKV or known pathogen infection (viral DNA, immunohistochemical cytology positive); contraindications or invalid to anti-microbial drugs
  • Subjects with virus DNA increased in the 2 consecutive peripheral blood samples (≥ 1000 genomic copies/ml blood) at least 24 hours apart
  • Initial hematopoietic reconstitution: neutrophils (ANC) ≥ 0.5x109 / L, platelet (PLT) ≥ 20x109 / L
  • Patients with pahogen disease (organ/ tissue infiltration) symptoms, fever, diarrhea, or lymphadenopathy, regardless of the level of peripheral blood virus DNA, and confirmed by the presence of viral DNA or microbial antigens within body fluid or biopsy
  • The subject / guardian has signed a written consent form before any trial begins; Proper renal and hepatic functions (ULN denotes "upper limit of normal range"):
  • Creatinine ≤ 2*ULN
  • Bilirubin ≤ 2*ULN
  • SGOT ≤ 3*ULN
  • SGPT≤ 3*ULN; If CTL is not from the patient's own, then the provider of CTLs needs to meet the following criteria:
  • Did not receive chemotherapy or radiotherapy within 4 weeks prior to blood collection, and did not take any steroids for the previous week, did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics
  • White blood cells ≥ 3,500 / μl, lymphocytes ≥ 750 / μl
  • Obtain a signed informed consent from the patient and / or the guardian or the donor of the BMT recipient
  • Human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or tuberculosis (TB) test is negative
  • Physical examination in line with the standard of healthy blood donors

Who cannot take part

  • Subject participated in other investigational somatic cell therapies within past 30 days
  • Subject infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), or HTLV (HTLV antibody positive)
  • GVHD (graft-versus-host disease) performance score at II-IV
  • Subject is albumin-intolerant
  • Subject with life expectancy less than 4 weeks
  • Subject with positive pregnancy test result

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Epstein Barr Virus (EBV) or Cytomegalovirus (CMV) infection results in significant morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients. HSCT patients often face opportunistic infections due to the immunosuppressive state during transplantation. Antimicrobial drugs are usually used for prophylactic purposes and for treatment after early detectable infections. Unfortunately, some patients develop resistance to such drug treatment. In addition to HSCT patient, immune compromised patient may also be victim to opportunistic infections. Many infections can be effectively managed by functional immune recovery. In this study, the safety and efficacy of microbial-specific cytotoxic T lymphocytes (CTLs) will be investigated.

The group in the trial

  • Infusion of pathogen-specific CTLsTreatment being tested

    Repetitive CTL infusions to treat microbial infections

    Treatment: pathogen-specific CTLs

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I/II Multicenter Trial of Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Record updated
2 November 2026